Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Agomelatine in pediatric patients with moderate to severe major depressive disorder: an open-label extension study

European Child & Adolescent Psychiatry(2024)10.1007/s00787-024-02587-4Source: DataRank Database

Agomelatine in pediatric patients with moderate to severe major depressive disorder: an open-label extension study is a research paper published in European Child & Adolescent Psychiatry (2024). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

Linked data & code

eudract

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 0.32)OA: hybridTopics (54)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Jörg M. Fegert ORCID,F. Picarel-Blanchot ORCID,Ute C. Marx ORCID,Lucie Truffaut-Chalet,Pierre‐François Pénélaud

Live enrichment

PubMed:39390266 PMC:PMC12122571 OpenAlex:https://openalex.org/W4403294380

NIMH NIH HHS

Grant: U01 MH124639

NIMH NIH HHS

Grant: P50 MH115846

European Commission

Grant: 847818

Comorbid Analysis of Neurodevelopmental Disorders and Epilepsy

European Commission

Grant: 777394

Autism Innovative Medicine Studies – 2 – Trials

National Institutes of Health

Grant: 1U01MH124639-01

ProNET: Psychosis-Risk Outcomes Network

European Commission

Grant: 101034377

Psychiatric Ratings using Intermediate Stratified Markers 2

National Institutes of Health

Grant: 5P50MH115846-03

Laboratory for Early Psychosis Research (LEAP)

Servier France

FWCI

0.32

Citation Percentile

0.6%

Citation Trend

2025

hybridLicense: cc-by-nc-nd

journalhttps://link.springer.com/content/pdf/10.1007/s00787-024-02587-4.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00787-024-02587-4.pdf

publisherhttps://link.springer.com/article/10.1007/s00787-024-02587-4/fulltext.html

journalhttps://doi.org/10.1007/s00787-024-02587-4

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39390266

Fields of Study

Treatment of Major DepressionDiet and metabolism studiesStress Responses and CortisolHumansMajor Depressive DisorderAcetamidesFemaleAdolescentMaleDouble-Blind MethodChildFluoxetineTreatment OutcomeAntidepressive AgentsNaphthalenes

MeSH Terms

AcetamidesAdolescentAntidepressive AgentsChildDepressive Disorder, MajorMajor Depressive DisorderDouble-Blind MethodFemaleFluoxetineHumansMaleNaphthalenesTreatment Outcome

Keywords

AgomelatineChild and adolescent psychiatryPsychiatryMajor depressive disorderDepression (economics)PsychologyMedicineAntidepressantPediatricsMoodChildrenAdolescentPediatricOpen-label ExtensionMaleResearchNaphthalenesAntidepressive AgentsTreatment OutcomeDouble-Blind MethodFluoxetineAcetamidesMedical Neuroscience - Development and lifelong plasticityHumansFemaleChild

Agomelatine in pediatric patients with moderate to severe major depressive disorder: an open-label extension study

FAIR Checklist

Authors (8)

Funding (8 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)